These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32944199)

  • 1. Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK.
    Bowrin K; Briere JB; Levy P; Millier A; Tardu J; Toumi M
    J Mark Access Health Policy; 2020 Jun; 8(1):1782164. PubMed ID: 32944199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.
    Hersi AS; Osenenko KM; Kherraf SA; Aziz AA; Sambrook RJ
    Ann Saudi Med; 2019; 39(4):265-278. PubMed ID: 31381381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.
    Escobar Cervantes C; Martí-Almor J; Cabeza AIP; Bowrin K; Llorac Moix A; Genís Gironès M; Gasche D; Millier A; Tardu J; Toumi M; Briere JB
    PLoS One; 2022; 17(4):e0266658. PubMed ID: 35443000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France.
    Bowrin K; Briere JB; Fauchier L; Coleman C; Millier A; Toumi M; Clay E; Levy P
    PLoS One; 2020; 15(1):e0225301. PubMed ID: 31978044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
    Rudakova AV; Tatarskiĭ BA
    Kardiologiia; 2014; 54(7):43-52. PubMed ID: 25177813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care.
    Johnson ME; Lefèvre C; Collings SL; Evans D; Kloss S; Ridha E; Maguire A
    BMJ Open; 2016 Sep; 6(9):e011471. PubMed ID: 27678530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
    Collings SL; Lefèvre C; Johnson ME; Evans D; Hack G; Stynes G; Maguire A
    PLoS One; 2017; 12(10):e0185642. PubMed ID: 29016695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting.
    Athanasakis K; Karampli E; Tsounis D; Bilitou A; Kyriopoulos J
    Clin Drug Investig; 2015 Nov; 35(11):693-705. PubMed ID: 26385756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of rivaroxaban versus apixaban for the initial treatment of venous thromboembolism and extended prevention of recurrences in the UK.
    Folkerts K; Broughton J; Sheikh U; Mckaig S
    J Med Econ; 2019 Nov; 22(11):1179-1191. PubMed ID: 31433687
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation.
    Dorian P; Kongnakorn T; Phatak H; Rublee DA; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Lip GY
    Eur Heart J; 2014 Jul; 35(28):1897-906. PubMed ID: 24513791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings.
    de Jong LA; Groeneveld J; Stevanovic J; Rila H; Tieleman RG; Huisman MV; Postma MJ; van Hulst M
    PLoS One; 2019; 14(9):e0222658. PubMed ID: 31527894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stroke and systemic embolism prevention in patients with atrial fibrillation in Belgium: comparative cost effectiveness of new oral anticoagulants and warfarin.
    Kongnakorn T; Lanitis T; Annemans L; Thijs V; Goethals M; Marbaix S; Wautrecht JC
    Clin Drug Investig; 2015 Feb; 35(2):109-19. PubMed ID: 25511639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis.
    de Jong LA; Gout-Zwart JJ; van den Bosch M; Koops M; Postma MJ
    J Med Econ; 2019 Apr; 22(4):306-318. PubMed ID: 30614320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States.
    Mohan A; Damgacioglu H; Deshmukh AA; Chen H; Wanat M; Essien EJ; Paranjpe R; Fatima B; Abughosh S
    Expert Rev Pharmacoecon Outcomes Res; 2024 Sep; ():1-8. PubMed ID: 39225337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation.
    Briere JB; Wu O; Bowrin K; Millier A; Toumi M; Taieb V; Levy P; Coleman CI
    Curr Med Res Opin; 2019 Nov; 35(11):1867-1872. PubMed ID: 31328580
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria.
    Aoudia Y; Kongnakorn T; Merinopoulou E; Bettayeb MS; Kherraf SA
    J Health Econ Outcomes Res; 2017; 5(1):39-54. PubMed ID: 37664691
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
    Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
    Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
    Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
    J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.